Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1360 • ACR Convergence 2024
Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Urbano Sbarigia¹, Jing Zhao², Jackie Kwong², Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Despite scientific advances and the availability of new treatments for rheumatoid arthritis (RA), many RA patients still cannot achieve the therapeutic goal of low…
Abstract Number: 1376 • ACR Convergence 2024
Comparison of the Efficacy of DMARDs in Phase 3 Trials of Different Populations Used in FDA Approvals for Rheumatoid Arthritis Since 2010
Catherine Emanuel¹ and Ajay Aggarwal², ¹Aclaris Therapeutics Inc., St Louis, MO, ²Aclaris Therapeutics, Inc., Wellesley, MA
Background/Purpose: Varying mechanisms of action are required to address the needs of rheumatoid arthritis patients with different levels of severity. Since 2010, all new FDA…
Abstract Number: 1393 • ACR Convergence 2024
Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials
Roy Fleischmann¹, Zoltán Szekanecz², Eduardo Mysler³, Kevin Winthrop⁴, Kunihiro Yamaoka⁵, Kirsten Famulla⁶, Yanna Song⁷, Birgit Kovacs⁷, Sander Strengholt⁸ and Gerd Burmester⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Debrecen, Debrecen, Hungary, ³Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, ⁴School of Medicine, Oregon Health and Science University, Portland, OR, ⁵Kitasato University School of Medicine, Sagamihara, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, ⁷AbbVie, North Chicago, IL, ⁸AbbVie Inc., North Chicago, IL, ⁹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Patients with RA are at a heightened risk of developing significant adverse events (AEs) such as MACE, VTE, and serious infectious events (SIE). Limited…
Abstract Number: 1661 • ACR Convergence 2024
Rheumatoid Arthritis Synovial Fibroblast Modulation of T Cell Activation
Melissa Romoff¹, Daniel Ramirez², Edward Dicarlo³, Susan Goodman⁴, Alexander Rudenska⁵, Laura Donlin¹ and Melanie Smith¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Cartago, Costa Rica, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York 10025, NY, ⁵Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: In the rheumatoid arthritis (RA) joint, resident synovial fibroblasts (FLS) interact with infiltrating leukocytes. We previously identified a population of sublining FLS responsive to…
Abstract Number: 1743 • ACR Convergence 2024
What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Jing Zhao¹, Urbano Sbarigia², Jackie Kwong¹, Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
Abstract Number: 1871 • ACR Convergence 2024
A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population
Tada Vargas¹, Lauren Vanderlinden², Patrick Carry³, Kristen Demoruelle⁴, Marie Feser¹, Katerina Kechris⁵, Jane Buckner⁶, William Robinson⁷, Gary Firestein⁸, Michael Holers¹, Kevin Deane⁹ and Jill Norris¹⁰, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Colorado School of Public Health, Monument, CO, ³Department of Orthopedics, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO, ⁵Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Benaroya Research Institute, Seattle, WA, ⁷Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA, ⁸University of California, San Diego, San Diego, CA, ⁹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹⁰Colorado School of Public Health, Denver, CO
Background/Purpose: Serum autoantibodies, such as ACPA and RF, are commonly detectable prior to the development of seropositive clinical RA; however, not all individuals with these…
Abstract Number: 1954 • ACR Convergence 2024
Examination of Rehabilitation Referrals from Rheumatology Practices for Adults with Rheumatoid Arthritis in the RISE Registry: A Feasibility and Descriptive Study
Louise Thoma¹, Jing Li² and Gabriela Schmajuk³, ¹University of North Carolina, Chapel Hill, NC, ²University of California, San Francisco, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Adults with rheumatoid arthritis (RA) commonly report functional limitations, pain, and fatigue that contribute to diminished quality of life and limit participation in valued…
Abstract Number: 2155 • ACR Convergence 2024
Direct Comparison of Sleep Quality and Risk Factors for Poor Sleep Across Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis
Dagna Polak¹, Mateusz Wilk², Piotr Kuszmiersz¹, Glenn Haugeberg³, Mariusz Korkosz⁴ and Zofia Guła⁴, ¹University Hospital in Cracow, Kraków, Poland, ²Univesity Hospital in Cracow, Kraków, Poland, ³Sørlandet Hospital, Kristiansand, Kristiansand, Norway, ⁴Department of Rheumatology and Immunology, Jagiellonian University Medical College, Kraków, Poland

Background/Purpose: Sleep disorders are common among patients with inflammatory arthritis (IA) and have probably bilateral influence on disease activity and quality of life. Pathomechanism of…
Abstract Number: 2224 • ACR Convergence 2024
Age of Onset of Rheumatoid Arthritis and Radiographic Changes
Masaru Shimizu¹, Misti Paudel², Nancy Shadick³, Michael Weinblatt⁴ and Daniel Solomon⁵, ¹University of Tsukuba, Yokohama, Kanagawa, Japan, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Brigham and Women's Hospital, Newton, MA

Background/Purpose: Epidemiological studies have shown that the age of onset for rheumatoid arthritis (RA) is increasing. However, associations between age of onset and joint erosion…
Abstract Number: 2240 • ACR Convergence 2024
Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis
George Karpouzas¹, Piet Van RIel², Elena Myasoedova³, Miguel Angel Gonzalez-Gay⁴, alfonso Corrales-Martínez⁵, Solbritt Rantapaa-Dahlqvist⁶, Petros Sfikakis⁷, Patrick Dessein⁸, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawy¹¹, Virginia Pascual Ramos¹², Irazu Contreras Yanez¹³, Iris Jazmín Colunga Pedraza¹⁴, Dionicio Galarza-Delgado¹⁵, jose Ramon Azpiri-Lopez¹⁶, Anne Grete Semb¹⁷, Patrick Durez¹⁸, Durga P Misra¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and ATACC-RA, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Radboud University Medical Center, Nijmegen, Netherlands, ³Mayo Clinic, Rochester, MN, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Umeå University, Umeå, Sweden, ⁷Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸University of Witwatersrand, Johannesburg, South Africa, ⁹University of Witwatersrand, Johanessburg, South Africa, ¹⁰University of Mannitoba, Winnipeg, Canada, ¹¹University of Mannitoba, Winnipeg, MB, Canada, ¹²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ¹³Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁶Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁷Diakonhjemmet Hospital, Oslo, Norway, ¹⁸UCLouvain, Louvain, Belgium, ¹⁹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: Disease activity was linked to cardiovascular (CV) risk in rheumatoid arthritis (RA). Anticitrullinated protein antibody (ACPA) positivity associated with greater synovial inflammation, tumor necrosis…
Abstract Number: 2260 • ACR Convergence 2024
Statin Use in Patients with Rheumatoid Arthritis (RA) and Osteoarthritis: Are RA Patients More Likely to Receive Statins?
Axi Patel¹, Pim Jetanalin², WL Galanter¹, Elaine Adams³ and HJ CHANG², ¹University of Illinois at Chicago; Jesse Brown VA Medical Center, CHICAGO, IL, ²RHEUMATOLOGIST, CHICAGO, IL, ³Jesse Brown VA Medical Center, La Grange, IL
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD) partly due to accelerated atherosclerosis from chronic inflammation. However, this increased risk…
Abstract Number: 2278 • ACR Convergence 2024
Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study
Olga Tsyruk¹, Marina Birck², Sasha Bernatsky², Luck Lukusa³, Denis Choquette⁴, Gilles Boire⁵ and Walter Maksymowych⁶, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rhumadata™, Montreal, QC, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment adherence is crucial to optimizing outcomes in rheumatic diseases. Suboptimal adherence is common with inflammatory and chronic diseases, often treated with biologics, including…
Abstract Number: 2541 • ACR Convergence 2024
Probiotic Modulation of Gut Microbiota Mitigates Early Rheumatoid Arthritis Progression: Insights from Pre-Clinical Models
Tong Wu¹, Yanhong Li², Yubin Luo¹ and Yi Liu³, ¹West China Hospital, Sichuan University, Cheng Du, China (People's Republic), ²West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, ³West China Hospital of Sichuan University, Chengdu, Sichuan, China
Background/Purpose: Rheumatoid arthritis (RA) progression, categorized by EULAR into six stages, includes pre-clinical RA (Pre-RA)[1], where mucosal surfaces are implicated as initiators of autoimmune responses…
Abstract Number: 2664 • ACR Convergence 2024
BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease
Laura Bucci¹, Melanie Hagen², Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer², ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
Abstract Number: 0042 • ACR Convergence 2024
Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model
Eva Philippon¹, Jan Piet van Hamburg¹, Lisanne van Rooijen¹, Gary Sims², Conny Van der Laken³ and Sander Tas⁴, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ³Amsterdam UMC - location VUMC, Amsterdam, Netherlands, ⁴Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder characterized by chronic and destructive joint inflammation. Key features of RA include synovial cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].